Literature DB >> 20547987

Personalizing therapy for ovarian cancer: BRCAness and beyond.

Robert C Bast, Gordon B Mills.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20547987     DOI： 10.1200/JCO.2010.28.5791

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  33 in total

1.  Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival.

Authors:  Joyce Liu; Mihaela C Cristea; Paul Frankel; Susan L Neuhausen; Linda Steele; Verena Engelstaedter; Ursula Matulonis; Sharon Sand; Nadine Tung; Judy E Garber; Jeffrey N Weitzel
Journal:  Cancer Genet       Date:  2012 Jan-Feb

2.  Using distance covariance for improved variable selection with application to learning genetic risk models.

Authors:  Jing Kong; Sijian Wang; Grace Wahba
Journal:  Stat Med       Date:  2015-01-29       Impact factor: 2.373

Review 3.  'BRCAness' and its implications for platinum action in gynecologic cancer.

Authors:  Franco Muggia; Tamar Safra
Journal:  Anticancer Res       Date:  2014-02       Impact factor: 2.480

4.  A conditional mouse model for measuring the frequency of homologous recombination events in vivo in the absence of essential genes.

Authors:  Adam D Brown; Alison B Claybon; Alexander J R Bishop
Journal:  Mol Cell Biol       Date:  2011-06-27       Impact factor: 4.272

Review 5.  Molecular approaches to personalizing management of ovarian cancer.

Authors:  R C Bast
Journal:  Ann Oncol       Date:  2011-12       Impact factor: 32.976

Review 6.  Molecular targeted therapy in ovarian cancer: what is on the horizon?

Authors:  Roshni Kalachand; Bryan T Hennessy; Maurie Markman
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

7.  Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells.

Authors:  Lizhou Jia; Shiwu Zhang; Yanfen Ye; Xin Li; Imelda Mercado-Uribe; Robert C Bast; Jinsong Liu
Journal:  Cancer Lett       Date:  2012-08-15       Impact factor: 8.679

8.  Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.

Authors:  Poorval M Joshi; Shari L Sutor; Catherine J Huntoon; Larry M Karnitz
Journal:  J Biol Chem       Date:  2014-02-19       Impact factor: 5.157

9.  Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells.

Authors:  Bin-Yong Liang; Min Xiong; Gui-Bao Ji; Er-Lei Zhang; Zun-Yi Zhang; Ke-Shuai Dong; Xiao-Ping Chen; Zhi-Yong Huang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-07-31

10.  In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.

Authors:  Mariam M AlHilli; Marc A Becker; S John Weroha; Karen S Flatten; Rachel M Hurley; Maria I Harrell; Ann L Oberg; Matt J Maurer; Kieran M Hawthorne; Xiaonan Hou; Sean C Harrington; Sarah McKinstry; X Wei Meng; Keith M Wilcoxen; Kimberly R Kalli; Elizabeth M Swisher; Scott H Kaufmann; Paul Haluska
Journal:  Gynecol Oncol       Date:  2016-09-08       Impact factor: 5.482
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.